In AML, TIGIT blockade therapy can effectively reverse TIGIT-mediated suppression of IFN-γ secretion in NK cells while augmenting their cytotoxic activity, thus offering a promising therapeutic target for AML treatment [164]. This evidence concerns the gene IFNG and acute myeloid leukemia.